Hiroyuki Okuzawa

Representative Director, President and CEO, Daiichi Sankyo

About

Hiroyuki Okuzawa is the representative director, president and chief executive officer of Daiichi Sankyo, a Japanese drug maker. The board named him CEO on 31 January 2025 and the role began on 1 April 2025, when Sunao Manabe became executive chairperson. He joined Sankyo, one of the companies that formed Daiichi Sankyo, in April 1986 and had served as president and chief operating officer since April 2023.

At the company he led the ASCA Company from April 2018, headed corporate planning and served as chief financial officer from April 2021, and joined the board in June 2021. Whoo also has pages for Naoki Okamura of Astellas Pharma and Julie Kim of Takeda, leaders of other Japanese drug makers.

Whoo compiled this page from public sources: Daiichi Sankyo leadership page, BioSpectrum Asia, January 2025, The Shashi. It is not affiliated with or endorsed by Hiroyuki Okuzawa. Are you Hiroyuki Okuzawa? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

Representative Director, President and CEO — Daiichi Sankyo


April 2025 – Present

  • Succeeded Sunao Manabe, who became executive chairperson

Representative Director, President and COO — Daiichi Sankyo


April 2023 – March 2025

Director, Head of Corporate Planning and Management Division, CFO — Daiichi Sankyo


June 2021 – March 2023

President — ASCA Company, Daiichi Sankyo


April 2018

Joined Sankyo


April 1986

Education

Education


Not published in sources

Projects